When Switzerland’s two biggest pharmaceutical companies are doing well, that’s usually a reason to celebrate. Swissinfo journalist Jessica Davis Plüss examines why Swiss politicians and industry leaders are instead calling for urgent reforms to keep the country attractive to pharma. Last year was a good year for Swiss pharma. Roche’s sales rose 7% (at constant exchange rates) to CHF61.5 billion ($79.8 billion), driven by strong demand for drugs for multiple sclerosis, eye diseases and Haemophilia A. With ten new molecules entering late-stage clinical trials, 2025 was “very much a record year for Roche”, said CEO Thomas Schinecker at the company’s annual results media conference in January. Its cross-town rival, Novartis, was also upbeat about 2025, with sales of key brands “well above expectations”, according to its annual report, enough to boost CEO Vas Narasimhan’s compensation by 30%. Even with generic competition expected to dent sales in 2026, Novartis’ US shares were trading ...
Full story here
Are you the author?
Previous post
See more for
Tags: Featured,newsletter
Home › 3) Swiss Markets and News › 3.) Swissinfo Business and Economy › Swiss pharma’s global success meets worries at home
Permanent link to this article: https://snbchf.com/2026/02/swiss-pharma-global-success-meets-worries/
Receive a Daily Mail from this Blog
Live Currency Cross Rates
On Swiss National Bank
-
SNB Sight Deposits: decreased by 5.3 billion francs compared to the previous week
4 days ago -
SNB’s Chairman Schlegel: A few months of negative inflation wouldn’t be a problem
24 days ago -
2025-07-31 – Interim results of the Swiss National Bank as at 30 June 2025
2025-07-31 -
SNB Brings Back Zero Percent Interest Rates
2025-06-26 -
Hold-up sur l’eau potable (2/2) : la supercherie de « l’hydrogène vert ». Par Vincent Held
2025-06-24
Main SNB Background Info
-
SNB Sight Deposits: decreased by 5.3 billion francs compared to the previous week
4 days ago -
The Secret History Of The Banking Crisis
2017-08-14 -
SNB Balance Sheet Now Over 100 percent GDP
2016-08-29 -
The relationship between CHF and gold
2016-07-23 -
CHF Price Movements: Correlations between CHF and the German Economy
2016-07-22
Featured and recent
-
Epstein-Files: Opfer fordert Haftbefehl gegen Selenski!
-
Trump beendet Obamas CO2 Doktrin! Luisa Neubauer springt an die Decke! -
Olaudah Equiano’s Manumission: Regulatory Barriers to Freedom
-
Kaufe keine aktiven ETFs -
Goldman Sachs top lawyer to step down after lying about Epstein connections
-
Baerbocks haarsträubende EPSTEIN Aussagen! -
Tech Amazon’s Ring cancels Flock partnership amid Super Bowl ad backlash
-
The Dollar is Firm Ahead of January CPI -
The Putnam Twist: The End of Value
-
Warsh May Not Be the Hawk Wall Street Expects
More from this category
- Olaudah Equiano’s Manumission: Regulatory Barriers to Freedom
13 Feb 2026
- Goldman Sachs top lawyer to step down after lying about Epstein connections
13 Feb 2026
- Tech Amazon’s Ring cancels Flock partnership amid Super Bowl ad backlash
13 Feb 2026
The Dollar is Firm Ahead of January CPI13 Feb 2026
- The Putnam Twist: The End of Value
13 Feb 2026
- Warsh May Not Be the Hawk Wall Street Expects
13 Feb 2026
Financial Nihilism & The Trap Young Investors Are Walking Into13 Feb 2026
Century Bonds: A Long Term Bet On Google13 Feb 2026
- The Real Numbers: Counting Gaza’s Dead and Disappeared
13 Feb 2026
BitGo and 21Shares Expand Partnership Across US and Europe for Crypto ETPs13 Feb 2026
- Swiss pharma’s global success meets worries at home
13 Feb 2026
- Proven Petroleum Reserves and the Myth of “Peak Oil”
13 Feb 2026
The ECB Unexpectedly Raises Rates But Pauses12 Feb 2026
- Understanding Different Types of Investment Vehicles: Stocks, Bonds, and Mutual Funds
12 Feb 2026
- The Pros and Cons of High-Yield Bonds
12 Feb 2026
- How to Avoid Common Bond Investing Mistakes
12 Feb 2026
- The Pros and Cons of Investing in Gold and Other Precious Metals
12 Feb 2026
- How to Buy Commodity ETFs: A Guide for Investors
12 Feb 2026
- The Different Types of Commodity Investments and Their Characteristics
12 Feb 2026
- Olaudah Equiano’s Manumission: Regulatory Barriers to Freedom
12 Feb 2026














